Id |
Subject |
Object |
Predicate |
Lexical cue |
T88 |
0-64 |
Sentence |
denotes |
Table 1 Antiviral AgNPs and Their Possible Mechanisms of Action |
T89 |
65-136 |
Sentence |
denotes |
virus shape size (nm) active concentration mechanism of action ref |
T90 |
137-199 |
Sentence |
denotes |
HIV-1 spherical 1–10 25 μg/mL interaction with gp120 (11) |
T91 |
200-261 |
Sentence |
denotes |
HIV-1 IIIB – 30–50 440 μg/mL interaction with gp120 (19) |
T92 |
262-387 |
Sentence |
denotes |
HSV-1, HSV-2, and HPIV-3 – 20–50 not available possible interaction directly with the viral envelope or its protein (20) |
T93 |
388-495 |
Sentence |
denotes |
Adenovirus type 3 spherical 5–18 25 μg/mL direct destruction of virus particles and DNA structure (15) |
T94 |
496-657 |
Sentence |
denotes |
H1N1 influenza A virus spherical 5–20 12.5 μg/mL inhibition of respiratory enzymes and electron transport components and interference with DNA function (21) |
T95 |
658-765 |
Sentence |
denotes |
HBV spherical 10–50 5 μM interaction with double-stranded DNA and/or binding with viral particles (16) |
T96 |
766-846 |
Sentence |
denotes |
PPRV spherical 5–30 11.1 μg/mL interaction with virus surface and core (12) |
T97 |
847-937 |
Sentence |
denotes |
Vaccinia virus spherical 25 not available preventing viral entry into host cells (13) |
T98 |
938-1038 |
Sentence |
denotes |
Monkey pox virus (MPV) – 10–80 12.5 μg/mL blocking virus-host cell binding and penetration (22) |
T99 |
1039-1131 |
Sentence |
denotes |
Tacaribe virus (TCRV) – 5–10 25 μg/mL inactivation of virus particles before entry (23) |
T100 |
1132-1243 |
Sentence |
denotes |
Poliovirus spherical 4–9 3.1 ppm preventing viral particles from binding to the receptors of RD cells (24) |
T101 |
1244-1357 |
Sentence |
denotes |
TGEV spherical <20 12.5 μg/mL direct interaction with TGEV surface protein, such as TGEV S glycoprotein (18) |
T102 |
1358-1377 |
Sentence |
denotes |
linear 60000–80000 |